Immunomedics Revenue and Competitors
Estimated Revenue & Valuation
- Immunomedics's estimated annual revenue is currently $34.6M per year.
- Immunomedics received $125.0M in venture funding in May 2017.
- Immunomedics's estimated revenue per employee is $288,042
- Immunomedics's total funding is $30M.
- Immunomedics has 120 Employees.
- Immunomedics grew their employee count by -8% last year.
Immunomedics Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Immunomedics?
Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer and other serious diseases. Immunomedics corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of antibody-drug conjugates.keywords:Biotechnology,Cleantech,Healthcare,Medical Diagnostics,Pharmaceuticals,Wind Power
Number of Employees
Employee Growth %
Gilead raised eyebrows in 2020 when it agreed to buy Immunomedics for about $21 billion, a substantial premium for a company that was...
Under a proposed settlement, Gilead Sciences' Immunomedics would shell out $4 million to resolve a lawsuit alleging it violated securities laws...
Immunomedics Inc. investors who say the company misled them about cancer drug data presentations asked a federal judge in New Jersey for...
Immunomedics, Inc. IMMU was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid ...
12, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|2015-02-09||$96.4M||Undisclosed||Goldman, Sachs & Co.||Article|